India
Tata Memorial Centre - Tata Memorial Hospital
atezolizumab, PD-L1 inhibitor, IPSOS, elderly, Eastern Cooperative Oncology Group performance status (ECOG PS), non-small cell lung cancer (NSCLC), phase III, overall survival, chemotherapy, first-line, gemcitabine, vinorelbine, platinum-ineligible
Reirradiation, Head and Neck Cancers, Patient selection, Outcomes, Toxicities
Anaplastic thyroid cancer, THRA mutations, lineage plasticity, exome sequencing
Radiotherapy, Second Primary Cancer, Oral Cavity Cancer, Head Neck Cancer
brain metastases, hippocampal-avoidance, WBRT, simultaneous integrated boost, NSCLC